Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2020-09-23 Share Issue/Capital Cha…
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
XVIVO Perfusion avser att genomföra en riktad nyemission av aktier
Share Issue/Capital Change Classification · 95% confidence The document is a press release from XVIVO Perfusion AB announcing their intention to conduct a directed share issue (nyemission) to raise capital for an acquisition and operational growth. It details the purpose of the capital raise, the involvement of investment banks, and includes standard legal disclaimers regarding securities offerings. Since this is an announcement of a capital-raising event (share issuance) rather than the final report or a simple notice of publication, it falls under the 'Share Issue/Capital Change' category.
2020-09-23 Swedish
XVIVO Perfusion intends to carry out a directed issue of shares
Capital/Financing Update Classification · 100% confidence The document is a press release from XVIVO Perfusion announcing the company's intention to carry out a 'directed issue of shares' (a private placement or capital raise). It details the purpose of the capital (financing an acquisition and regulatory processes), the involvement of investment banks, and the legal disclaimers associated with such a financial transaction. This falls squarely under the category of capital and financing updates.
2020-09-23 English
XVIVO Perfusion förvärvar det nederländska medicintekniska företaget Organ Assist och finansierar förvärvet genom en nyemission av aktier
M&A Activity Classification · 95% confidence The document is a press release from XVIVO Perfusion announcing the acquisition of Organ Assist and the associated financing through a directed share issue. It details the transaction terms, strategic rationale, and financial information, while also including standard legal disclaimers regarding securities offerings. Since this is a corporate announcement regarding an acquisition and a capital raise (share issue), it falls under the category of M&A activity (TAR) as it is the primary announcement of a merger/takeover bid.
2020-09-23 Swedish
XVIVO Perfusion to acquire the Dutch medtech company Organ Assist and finances the acquisition through a private placement of new shares
M&A Activity Classification · 95% confidence The document is a press release announcing a definitive agreement for XVIVO Perfusion to acquire Organ Assist. It details the purchase price, strategic rationale, and the financing method (a directed share issue). While it mentions a share issue, the primary purpose of the document is to announce a merger and acquisition (M&A) transaction. Therefore, it falls under the M&A Activity category.
2020-09-23 English
Changes in XVIVO Perfusion's Management Team
Board/Management Information Classification · 100% confidence The document is explicitly titled "Changes in XVIVO Perfusion's Management Team" and details the appointment of a new Chief Operating Officer (COO) and a new Chief Financial Officer (CFO). This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2020-09-21 English
Förändringar i XVIVO Perfusions ledningsgrupp
Board/Management Information Classification · 99% confidence The document is a press release dated September 21, 2020, announcing specific changes within the company's senior management team (CFO appointed as COO, new CFO named). This directly aligns with the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is short and is an announcement, not a comprehensive report like a 10-K or IR.
2020-09-21 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.